Securities and Exchange Commission including the LOXO-101 materials provided at the AACR-NCI-EORTC meeting. These materials will also be published to the Loxo Oncology website. Loxo Oncology expects to progress a RET inhibitor as its next Investigational New Medication application. Forthcoming Milestones for Loxo Oncology Loxo Oncology continues to make significant progress across its pipeline. Presentation of additional data from the ongoing Phase 1 study of LOXO-101 at a medical interacting with in 2016.The analysis revealed that patients who lived in areas where polluting of the environment was above maximum amounts recommended by the World Health Organization were ten % much more likely to die than those in areas with lower degrees of pollution. But this increased risk of death had not been seen among individuals who took a course of antibiotics called macrolides, which include azithromycin and clarithromycin , based on the research presented Tuesday at a gathering of the European Respiratory Society in Amsterdam. ‘Short and long-term exposure to air pollution has been linked to an increase in deaths from respiratory illnesses, among vulnerable populations particularly. Lung transplant individuals are being among the most vulnerable because they have weakened immune systems because of the immunosuppressive drugs they have to try prevent organ rejection,’ study writer Dr.